EBESANAR
LIVE

Serial Number

79365162

Owner

RHEACELL GmbH & Co. KG

Attorney

Sean K. Owens

Filing Date

Dec 7, 2022

Add to watchlist:

No watchlists yet
View on USPTO

EBESANAR Trademark

Serial Number: 79365162 • Registration: 7470205

EBESANAR is a trademark filed by RHEACELL GmbH & Co. KG on December 7, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

RHEACELL GmbH & Co. KG (9 trademarks)

Im Neuenheimerfeld 517

Entity Type: 28

Trademark Details

Filing Date

December 7, 2022

Registration Date

August 13, 2024

Published for Opposition

May 28, 2024

Goods & Services

Stem cells for scientific use; stem cells for research use; cell growth media for growing cells for scientific use; stem cells other than for medical or veterinary purposes, namely, stem cells for aesthetic purposes excluding all medical or veterinary purposes

Pharmaceutical drug development; scientific and technological services, namely, scientific research in the field of genetics; research and development services in the fields of cell diagnostics, cell therapy; scientific research for medical purposes in the field of genetics; stem cell research services; scientific research; scientific research and development; scientific research, testing and analysis services in the field of genetics; medical research; biomedical research services; research and development in the field of biotechnology; research and development in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; research and development in the field of gene expression systems; research and development in the field of vaccines; research and development of new products; industrial process research, namely, research and development of new products; research and development of new products for the pharmaceutical industry; research and development of new products for others; consultancy in the field of pharmaceutical research; providing information about medical and scientific research for pharmaceutical products; preparation of reports relating to scientific research

Drugs for medical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for treating skin disorders; diagnostic agents, namely, diagnostic radiopharmaceutical agent for use in PET imaging; pharmaceutical preparations, namely, pharmaceutical preparations for treating skin disorders; preparations for medical purposes, namely, pharmaceutical preparations for treating skin disorders; preparations for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical cell preparations for treating skin disorders; substances for medical use, namely, pharmaceutical preparations for treating skin disorders; substances for biomedical purposes, namely, pharmaceutical preparations for treating skin disorders; live implants for pharmaceutical purposes, namely, implants comprising living tissue for pharmaceutical purposes; biochemical and chemical products for medical use, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical products for pharmaceutical purposes, namely, pharmaceutical preparations for treating skin disorders; biochemical and chemical diagnostic preparations for medical purposes; proteins for medical purposes, namely, protein arrays for medical diagnosis purposes; biological preparations for medical and veterinary purposes, namely, pharmaceutical preparations for treating skin disorders; pharmaceutical and veterinary preparations for external and systemic use, namely, pharmaceutical preparations for treating skin wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes, namely, pharmaceutical preparations for treating skin disorders; medical dressings; preparations for wound treating and healing, namely, pharmaceutical preparations for treating skin wounds; pharmaceutical preparations for treating skin wounds; stem cells for medical purposes; stem cells for veterinary purposes; somatic stem cell therapeutics, namely, somatic stem cells for medical or veterinary use; cells for medical use in the nature of fibroblasts for medical purposes; cells for medical use in the nature of fibroblasts for surgical beauty purposes; pharmaceutical implants, namely, implantable pharmaceutical preparations for treating cancer; cells for medical use in the nature of surgical implants derived from stem cells; cells for medical use in the nature of surgical implants derived from fibroblasts; cells for medical use in the nature of biological tissue for implantation; growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, living cells for medical use; biotechnologically engineered tissue products, namely, cells for medical use

Medical services; medical diagnostic testing, monitoring and reporting services; medical assistance; health clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, providing laser therapy for treating medical conditions; medical services in the field of regenerative medicine; medical services relating to the cultivation and procurement of stem cells; medical services in connection with the cultivation and procurement of stem cells

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Feb 22, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 4, 2025 FICS
FINAL DISPOSITION PROCESSED
Feb 3, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 13, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 13, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 13, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 28, 2024 NPUB
PUBLISHED FOR OPPOSITION
May 28, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 8, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 18, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 18, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 17, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 17, 2024 TROA
REFUSAL PROCESSED BY IB
Nov 13, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 24, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 24, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 14, 2023 RFCR
NON-FINAL ACTION WRITTEN
Oct 13, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 21, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 17, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 16, 2023 REPR